GeneReach Biotechnology Corp.
TWO: 4171.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- De Yu Zhong
- Headquarters
- Taichung, Taiwan
- IPO year
- 2012
- Market cap
- NT$1.1B
- Website
- https://www.genereach.com
Loading 4171…
Loading profile data…Frequently asked questions about 4171
What does GeneReach Biotechnology Corp. (4171.TWO) do?
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers automatic nucleic acid extraction systems, prep homogenization system, and mini centrifuge equipment; and reagents and consumables, comprising human IVD assays, iiPCR specific reagents, taco nucle...
Where does 4171.TWO trade?
GeneReach Biotechnology Corp. (4171.TWO) trades on the Taipei Exchange.
What sector is 4171.TWO in?
GeneReach Biotechnology Corp. (4171.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of GeneReach Biotechnology Corp.?
De Yu Zhong is the chief executive officer of GeneReach Biotechnology Corp. (4171.TWO).
Where is GeneReach Biotechnology Corp. headquartered?
GeneReach Biotechnology Corp. is headquartered in Taiwan.
Does 4171.TWO pay a dividend?
GeneReach Biotechnology Corp. (4171.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4171.TWO go public?
GeneReach Biotechnology Corp. (4171.TWO) completed its initial public offering in 2012.